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Abstract 
 
 
PTPL1, a non-receptor type protein tyrosine phosphatase, has been involved in the 
regulation of apoptosis and invasiveness of various tumour cell types, but its role in 
prostate cancer remained to be investigated. We report here that downregulation of 
PTPL1 by small interfering RNA in PC3 cells decreases cell proliferation and 
concomitantly reduces the expression of cell cycle-related proteins such as cyclins E 
and B1, PCNA, PTTG1 and phospho-histone H3. PTPL1 downregulation also increases 
the invasion ability of PC3 cells through Matrigel coated membranes. cDNA array of 
PTPL1-silenced PC3 cells versus control cells showed an upregulation of invasion-
related genes such as uPA, uPAR, tPA, PAI-1, integrin α6 and osteopontin. This 
increased expression was also confirmed in PTPL1-silenced DU145 prostate cancer 
cells by quantitative real time PCR and Western blot. These findings suggest that 
PTPL1 is an important mediator of central cellular processes such as proliferation and 
invasion. 
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Introduction 
 
Prostate cancer is the most common non-skin cancer among men in most western 
populations [1]. Death from prostate cancer is primarily due to its metastasis to distal 
sites, predominantly to the bone [2]. The metastatic process consists of detachment of 
cancer cells from the primary tumor, adhesion to and degradation of the extracellular 
matrix to infiltrate the surrounding tissue, the invasion of blood and lymphatic vessels, 
and finally the establishment of metastases at secondary sites [3]. A prerequisite for 
invasion into surrounding tissue is a change in the overall cellular machinery controlling 
these processes and phosphorylation of tyrosine residues is usually a critical step for 
regulating activities of certain cellular proteins and subsequent activation/deactivation 
of their downstream signaling events. The family of protein tyrosine phosphatases 
(PTPs) is divided into two major subtypes: the receptor-like and the non-receptor 
subtype. Protein tyrosine phosphatase L1 (PTPL1, also known as PTPN13, FAP-1, 
PTP-BAS or hPTP1E) is a non-receptor tyrosine phosphatase. Besides its carboxy-
terminal catalytic domain, the protein structure comprises a kinase non-catalitic C-lobe 
(KIND) domain and two major domains: a FERM domain involved in plasma 
membrane and cytoskeleton binding and five PDZ domains. Those latter are protein-
protein interaction domains, with an important role in the assembly of supramolecular 
protein complexes [4, 5]. The role of PTPL1 in cancer remains controversial. There are 
data to support PTPL1 acting as both tumor promoter and suppressor in a variety of 
cancer models [5, 6]. In relation to its function as a tumor suppressor, a study of the 
tyrosine phosphatome of colorectal cancers identified PTPN13 gene as among the most 
frequently mutated PTPs [7]. Data regarding PTPL1 and cell cycle are scanty. 
Herrmann et al., [8] demonstrated that PTPL1 is capable to interact with the spindle 
midzone microtubules and that its localization is regulated in a cell cycle-dependent 
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manner. Moreover, PTPL1 overexpression induces defects in cytokinesis. Also, it has 
been shown that PTPL1 functions downstream of cAMP signaling and plays an 
essential role in controlling meiotic resumption in Xenopus oocytes [9]. In relation to 
invasion, there are several reports addressing a role of PTPL1 in this process. In 
SKOV3 ovarian carcinoma cells infected with recombinant lentivirus carrying shRNA 
against PTPL1, Her2 phosphorylation induced by EGF and the invasive potential were 
increased compared to SKOV3 infected with virus carrying empty vector. PTPL1 
inhibits Her2 activity by dephosphorylating the signal domain of Her2 and plays a role 
in attenuating invasiveness and metastasis of Her2-overexpressing tumor cells [10]. 
Other study has shown that overexpression of PTPL1 reduced lysophosphatidic acid-
induced transwell cell migration and that suppression of endogenous PTPL1 expression 
significantly enhanced lysophosphatidic acid-induced cell migration in SKOV3 cells 
[11]. Also, it has been reported that HPV 16-mediated PTPL1 loss synergizes with 
ErbB2 activity during invasive growth in HPV-related head and neck cancers [12]. 
Recently, another study has addressed the role of PTPL1 in invasion in MCF7 breast 
cancer cells. In this setting, PTPL1 downregulation increased tumor growth in athymic 
mice and also enhanced several parameters associated with tumor progression, 
including cell proliferation on extracellular matrix components and cell invasion [13]. 
In this study, we investigate whether PTPL1 influences cell cycle and invasion 
in prostate cancer cells. We also identify cell cycle and invasion-related downstream 
targets induced upon PTPL1 silencing that point towards a role for PTPL1 in 
modulation of cell proliferation and negative regulation of invasion in prostate cancer. 
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Materials and methods 
 
Cell culture 
 
Human prostate cancer cell lines PC3 and DU145 were obtained from the Interlab Cell 
Line Collection (Genoa, Italy) and routinely grown in RPMI 1640 supplemented with 
10%  fetal bovine serum, 100 U/ml penicillin, 50 µg/ml streptomycin, HEPES buffer 10 
mM and 1 mM glutamine in a 37oC, humidified incubator under 5% CO2. Cells were 
harvested by trypsinization. 
 
Small interfering RNA 
 
Small interfering RNA (siRNA) transfections were carried out using the Dharmafect 
reagent (Thermo Fisher Dharmacon, Lafayette, CO) according to the manufacturer’s 
instructions. PTPL1-specific siRNA and the negative control siRNA were from Qiagen 
(Hilden, Germany) and used at 100 nM. Transfection efficiency was tested using 
PTPL1-specific siRNA labeled with Alexa Fluor 488 (Qiagen). At 24 h and 72 h  after 
silencing, the percentage of transfected cells were 61.7% and 26.7%, respectively. 
 
Western blotting 
 
Cells were lysed in Nonidet P-40 (NP40) lysis buffer (10 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 10% glycerol and 1% NP40). Equal amounts of total protein, as determined 
by using BCA protein assay (Pierce, Rockford, IL), were separated by SDS-PAGE on 
4-20% gradient polyacrylamide gels (Invitrogen, Carlsbad, CA). Gels were 
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electroblotted onto nitrocellulose membranes (GE Healthcare, Europe GmbH, 
Cerdanyola, Spain). Membranes were stained with Ponceau S to ensure that protein 
amounts were comparable. For immunodetection, blots were blocked in 1% blocking 
reagent (Roche, Mannheim, Germany) in 0.05% Tween 20-PBS for 1 h and incubated 
with primary antibody overnight at 4oC diluted in blocking buffer. Blots were then 
washed in 0.05% Tween 20-PBS and incubated with either goat anti-mouse (1:10,000; 
GE Healthcare) or goat anti-rabbit (1:20,000; GE Healthcare) peroxidase-labeled 
antibodies in blocking buffer for 1 h. Enhanced chemoluminescent system was applied 
according to the manufacturer’s protocol (GE Healthcare). Chemoluminiscent signal 
was detected on BioMax light films (Kodak, Rochester, NY) at different exposure 
times. Scanning densitometry was performed with QuantiScan software (Biosoft, 
Cambridge, UK). Arbitrary densitometric units of the protein of interest were corrected 
for those of β-actin. 
 
Antibodies 
 
Mouse monoclonal anti-β-actin was from Sigma (St. Louis, MO). Rabbit polyclonal 
anti-PTPL1, anti-phospho-histone H3 (Ser 10) and anti-uPA were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-PCNA was from Dako 
(Glostrup, Denmark). Rabbit polyclonal anti-PTTG1 was previously described [14]. 
Mouse monoclonal anti-cyclin B1 was from BD Biosciences (San Jose, CA), mouse 
monoclonal anti-cyclin E was from Monosan (Uden, The Netherlands), mouse 
monoclonal anti-active β-catenin (clone 8E7) was from Millipore (Temecula, CA, 
USA), rabbit polyclonal anti-integrin α6 was from Cell Signaling (Danvers, MA) and 
rabbit polyclonal anti-osteopontin was from Neomarkers (Fremont, CA) Dilutions used 
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in Western blots were anti- PTPL1 (1:500); anti-cyclin E (1:100); anti-PCNA 
(1:10000); anti-cyclin B1 (1:1000); anti-PTTG1 (1:1000); anti-phospho-Histone H3 
(Ser 10) (1:800); anti-uPA (1:500); anti- integrin α6 (1:500); anti-active β-catenin (1: 
300); anti-osteopontin (1:100); anti-β-actin (1:20000). 
 
Flow cytometric analysis of cell cycle 
 
Cells were trypsinized and fixed in 70% ethanol. Propidium iodide staining of nuclei 
was performed with a CycleTest Plus DNA reagent kit (BD Biosciences), and the DNA 
content was measured with a FACScan instrument (BD Biosciences). Data were 
acquired with CellQuest Pro software (BD Biosciences). ModFit LT2 software (Verity 
Software, Topsham, ME) was used to assess cell cycle. 
 
Proliferation assay 
 
Cells were seeded in a 24-wells plate and silenced with control siRNA or PTPL1 
siRNA. Cells were tripsinized and counted, using a hemocytometer, after 24 h, 48 h, 72 
h and 96 h of silencing respectively. 
 
BrdU incorporation assay 
 
Cells were labeled for 2 h with 10 µM bromodeoxyuridine (BrdU), harvested, and fixed 
in glycine:ethanol (3:7) at 4°C. A cell proliferation kit (Roche) was used to detect BrdU 
incorporation into cellular DNA by flow cytometry. Fluorescence data were acquired by 
using CellQuest Pro software. 
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Tumor cell migration and invasion assays 
 
To assess cell migration, a wound healing assay was performed. Cells were grown to 
near confluency on a 24-well plate. 24 h after silencing, a scratch was made on the cell 
monolayer using a sterile 200 µl pipette tip. The monolayer was washed twice and 
incubated for another 36 h. Cells were photographed at 0 h and 36 h under a Zeiss 
inverted microscope with Nomarski optics using a 16 objective and the wound areas 
were measured with ImageJ software (Rasband, W.S., U.S. National Institutes of 
Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2011). 
The invasion chamber consists of a 24-well plate with control inserts containing an 8-
µm pore-size polyethylene terephthalate (PET) membrane and Matrigel inserts (BD 
Biosciences) containing an 8-µm pore-size PET membrane coated with a thin layer of 
extracellular matrix (ECM). Cells silenced during 24 h were tripsinized and suspended 
in serum-free RPMI 1640 and added to the upper chamber at 2 x 104 cells/insert. The 
lower chamber was filled with medium containing 5% fetal bovine serum as 
chemoattractant. After 48 h of culture, the upper surface of the inserts were wiped with 
cotton swabs, and the inserts were stained with Quick Panoptic (QCA, Tarragona, 
Spain) and evaluated under light microscopy. 
 
Reverse-transcription and quantitative PCR 
 
Total RNA was extracted using the Purescript RNA Isolation Kit (Gentra, Minneapolis, 
MN) according to the manufacturer's protocol. 1 µg of total RNA was subjected to 
DNase I (Invitrogen) digestion and subsequently processed to cDNA by reverse 
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transcription with Transcriptor First Strand cDNA Synthesis Kit (Roche) according to 
the manufacturer's protocol. PCR reactions were performed in a 25 µl reaction volume 
on the SmartCycler II Real-Time PCR Detection System (Cepheid, Sunnyvale, CA) 
using the QuantiMix Easy SyG kit (Biotools, Madrid, Spain) and 500 nM of each 
specific primer. The levels of PTPL1 and the housekeeping gene HPRT1 in each sample 
were quantified by measuring the Ct values in duplicate. These mean Ct values were 
transformed to quantities using the delta-Ct method [15]. The sample with the lowest 
value was assigned the value 1. The quantity of PTPL1 transcript was divided by the 
quantity of HPRT1 to obtain a normalized value. 
 
Microarray hybridization and analysis 
 
Total RNA was extracted from siRNA control and siRNA PTPL1 PC3 cells with 
RNeasy® Mini kit (Qiagen). Three micrograms of total RNA were biotin-labeled using 
GEArray AmpoLabeling LPR Kit (SABiosciences, Frederick, MD) and used to 
hybridize 96-gene cDNA pathway-specific arrays (Human extracellular & adhesion 
molecules GEArrays, SABiosciences), following manufacturer’s instructions. 
Chemoluminiscent signal was detected on BioMax light films at different exposure 
times. Films were scanned for densitometric analysis by using QuantiScan software. 
Raw densitometric values were corrected by substracting the average background of 
negative controls. Normalization was completed with the average of non-saturated 
signals from four different housekeeping genes. 
 
Statistics 
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Data comparing differences between two conditions were statistically analyzed, when 
indicated, using paired Student’s t test. Differences were considered significant when P 
< 0 .05. 
 
 
Results 
 
PTPL1-silenced PC3 cells exhibit changes in cell cycle profile 
 
We examined if PTPL1 silencing could modify the cell cycle distribution in prostate 
cancer PC3 cells. We therefore analyzed the DNA content of propidium iodide stained 
siRNA control and siRNA PTPL1 PC3 cells by flow cytometry at two time points, and 
percentage of cells in different phases of the cell cycle was computed. Cells silenced for 
PTPL1 during 72 h (Fig. 1A) showed an increase of 10.1% in G0   /G1 phase cells and a 
concomitant decrease of 7.0% in S phase and 3.1% in G2/M phase populations respect 
to siRNA control cells. Moreover, the difference in Go/G1 phase cells between siRNA 
control and siRNA PTPL1 cells was statistically significant (P < 0.05 from Student’s t 
test) (Fig. 1B). Similarly, PTPL1 silenced cells during 96 h (Fig. 1A) showed an 
increase of 8.9% in G0/G1 phase cells respect to siRNA control cells (P < 0.05 from 
Student’s t test) and a decrease of 6.6% and 2.3% in S and G2/M phase populations 
respectively (Fig. 1B). In order to confirm these results, a proliferation assay was 
realized by counting the cell number after 24 h, 48 h, 72 h and 96 h of PTPL1 or siRNA 
control silencing. At all time points, cell number was lower in PTPL1-silenced cells 
than in siRNA control cells, and the doubling time from 0 h to 96 h for siRNA control 
cells was 30.4 h and for siRNA PTPL1 cells was 38.2 h. Moreover, the difference 
between siRNA control and siRNA PTPL1 cells at 72 h and 96 h was statistically 
significant (P < 0.05 from Student’s t test) (Fig. 1C). To further confirm these results, 
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we realized a proliferation assay by means of detection of BrdU incorporation in DNA 
synthesizing cells by flow cytometry. According to cell cycle results, PC3 cells silenced 
for PTPL1 during 72 h showed a decrease of 8.3% in proliferating cells compared with 
siRNA control cells (20.5% ± 3.3 versus 28.8% ± 4.0), also in a statistically significant 
way (Fig. 1D). Finally, a Western blot analysis of several cell cycle-related proteins was 
performed after 72 h and 96 h of PTPL1 silencing. As presented in figure 1E, PC3 cells 
silenced for PTPL1 at both time points showed decreased cyclins E and B1, PTTG1, 
phospho-histone H3 and PCNA expression levels, according to diminished proliferation 
found in these conditions. 
 
PTPL1 silencing induces a more invasive phenotype in PC3 cells 
 
Next, a wound healing assay was performed to test the effect of PTPL1 silencing on cell 
migration (Fig. 2A). The difference between siRNA control and siRNA PTPL1 cells 
was not statistically significant, suggesting the absence of a migratory phenotype. Then, 
to test the invasion ability of PC3 cells silenced for PTPL1, we realized a Matrigel 
assay. PC3 siRNA control and siRNA PTPL1 cells were allowed to migrate through 
uncoated or Matrigel-coated inserts. Cells that migrated to the lower surface of each 
type of insert were photographed and counted under a light microscope. Percent of 
invasion was calculated as the number of cells migrating through the Matrigel insert 
(+ECM) relative to the migration through the control insert (ECM). We observed that 
silencing of PTPL1 increases the percentage of invading cells with 13.7% (23.6% ± 6.1 
versus 37.3% ± 4.2) (Fig. 2B), in a statistically significant way (P < 0.05). Therefore, 
downregulation of endogenous PTPL1 expression increases the invasive potential of 
PC3 cells. 
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PTPL1-silenced PC3 and DU145 cells show increased expression of invasion-related 
genes 
 
To confirm matrigel results, we performed a cDNA array of invasion-related genes. The 
gene expression profile of PTPL1-silenced PC3 cells as compared to siRNA control 
PC3 cells showed a set of differentially expressed genes. We focused on upregulated 
genes that were the following (fold increase between parentheses): Osteopontin (2,21), 
integrin α6 (2,16), PAI-1 (2,01), integrin β5 (1,95), uPA (1,74), tPA (1,73), uPAR 
(1,54) and laminin γ1 (1,51). Then, some of these upregulated genes were validated by 
quantitative real-time PCR (qPCR). Fig. 3A shows downregulation of PTPL1 mRNA in 
PC3 cells. qPCR results completely agree with those from the cDNA array. We 
observed an upregulation of uPA, uPAR, tPA, PAI-1 and integrin α6 in PTPL1 silenced 
cells as compared with siRNA control PC3 cells (Fig. 3B). This increased expression 
was statistically significant. To examine whether the results obtained in PC3 cells could 
be extended to another prostate cancer cell line, we perform the same qPCR analysis 
with control and PTPL1-silenced DU145 cells. Percentage of PTPL1 downregulation in 
DU145 cells is shown in Fig. 3A. uPA, uPAR and integrin α6 were also upregulated in 
PTPL1-silenced DU145 cells, in a statistically significant way (Fig. 3B). 
 
Invasion-related proteins are upregulated in PC3 and DU145 cells silenced for PTPL1 
 
Finally, to further verify array and qPCR results, we performed a Western blot analysis 
of uPA, integrin α6 and osteopontin proteins in control and PTPL1 silenced PC3 and 
DU145 cells during 72 h and 96 h. We also examined the expression level of active β-
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catenin, another protein involved in tumor invasion and a transcriptional regulator of 
uPA and uPAR in colorectal carcinoma [16, 17]. uPA and integrin α6 proteins were 
increased in both PTPL1-silenced PC3 and DU145 cells during 72 h and 96 h, 
confirming previous qPCR results. β-catenin was more active in both cell lines silenced 
for PTPL1 at both time points, and osteopontin expression was also elevated in both cell 
lines after 96 h of PTPL1 silencing (Fig.4). All these data point towards a role of PTPL1 
in the regulation of invasion-related proteins such as uPA, integrin α6, osteopontin or β-
catenin. 
 
Discussion 
 
Prostate carcinogenesis involves a multistep progression from precancerous cells to 
cells that proliferate locally and then metastasize. The influence of protein tyrosine 
phosphatase PTPL1 in cell cycle and proliferation has not been extensively studied. 
Available data point towards a role in cytokinesis in HeLa cells [8] and in meiosis in 
Xenopus oocytes [9]. We have shown here that downregulation of endogenous PTPL1 
by small interfering RNA induces changes in cell cycle profile. The expression level of 
several regulators of cell cycle also supports this result. Cyclin E is essential to drive 
G1/S transition [18] and PCNA plays a critical role in DNA replication [19]; thus, 
according to diminished S phase, cyclin E and PCNA expression level are also 
diminished in PTPL1-silenced PC3 cells. Moreover, cyclin B1 and PTTG1 proteins are 
elevated in mitosis [18, 20] and histone H3 becomes phosphorylated at Ser 10 at the end 
of prophase [21]. Also in agreement with the G2/M phase cells decrease, cyclin B1, 
PTTG1 and phospho-histone H3 protein levels were diminished in PTPL1-silenced 
cells. These data could indicate a role for PTPL1 in cell cycle regulation, as PTPL1 
silencing impairs progression through S and G2/M phases. In relation to invasion, it has 
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been reported that PTPL1 inhibit invasiveness of different cancer cells [10-13]. In line 
with these results, PTPL1 silencing in PC3 cells induces an increase in the percentage of 
invading cells (13.7%), supporting a role of PTPL1 in inhibition of invasion. This role 
was further supported by the cDNA array and qPCR results. Between the differentially 
upregulated genes in the array performed with siRNA control and PTPL1 PC3 cells, we 
found several components of the urokinase plasminogen activator (uPA) system, 
osteopontin and integrin α6. The uPA system consists of urokinase-type plasminogen 
activator (uPA), its receptor (uPAR), tissue-type plasminogen activator (tPA), 
plasminogen, and plasminogen activator inhibitors (PAIs). uPA is secreted as a 
zymogen (pro-uPA), and activation of pro-uPA is accelerated by its binding to uPAR 
[22]. The active uPA catalyzes the conversion of plasminogen to plasmin, which in turn 
degrades a variety of extracellular matrix components. Therefore, uPA and its receptor 
are considered to be regulators of tumor metastasis at different stages and represent an 
important therapeutic target. The activity and turnover of uPA are regulated by another 
member of the system, PAI-1, which is the primary endogenous inhibitor of uPA. 
According to its inhibitory function, PAI-1 was originally predicted to suppress cancer 
proliferation and metastasis. However, high levels of PAI-1 indicate a poor prognosis 
for survival in some human cancers [23, 24]. Additionally, it has been shown that both 
tumor derived uPA and tumor-stroma-induced PAI-1 play important roles in 
intraosseous metastatic prostate cancer growth through regulation of uPA-uPAR-PAI-1 
axis by autocrine/paracrine mechanisms [25]. Therefore, the uPA system is particularly 
associated with the process of metastasis. Specifically in prostate cancer, overexpression 
of both uPA and PAI-1 is associated with adverse pathologic features and higher risk of 
overall and aggressive disease recurrence in men treated with radical prostatectomy for 
clinically localized cancer [26]. Moreover, it has been demonstrated in PC3 cells that 
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RNA interference-directed knockdown of uPA and uPAR inhibits invasion, survival, 
and tumorigenicity in vivo [27]. Integrin α6, a laminin receptor, is also associated with 
an increased invasive potential of human prostate cancer cells in vitro and with the 
progression of human prostate carcinoma in human tissue biopsy material [28, 29]. 
Integrin α6 exists in the classical form (140 kDa) and in a smaller form (70 kDa) called 
α6p. This variant, present in prostate cancer tissue but absent in normal prostate, is 
produced by proteolytic cleavage of the integrin α6 by uPA in a plasmin-independent 
manner, enhancing cell invasion and migration on laminin [30]. Integrin α6 cleavage 
also allows extravasation of human prostate cancer cells from circulation to bone [31]. 
Osteopontin is overexpressed in a variety of cancers and is involved in invasion and 
metastasis [32]. Increased osteopontin expression correlates with Gleason score and 
decreased survival in prostate cancer patients [33]. In prostatectomy specimens, 
osteopontin expression is independently associated with biochemical recurrence [34]. 
Interestingly, osteopontin stimulates the secretion of uPA in breast cancer cells [35]. 
 
 
In conclusion, our data support a role for PTPL1 in cell cycle and invasion. 
PTPL1 downregulation in PC3 cells decreases cell proliferation, as well as expression 
of cyclins E and B1, PCNA, PTTG1 and phospho-histone H3 proteins. Suppression of 
PTPL1 endogenous expression in PC3 cells also elicits a more invasive phenotype in 
Matrigel assays. The increased invasive potential may be explained, at least in part, by 
the induction of well known mediators of invasion such as uPA system, osteopontin or 
β-catenin, that were also induced in PTPL1-silenced DU145 cells. Interestingly, it has 
been reported that PTPL1 interacts with APC (Adenomatous Polyposis Coli), a β-
catenin interacting protein [36], thus the influence of PTPL1 on uPA system, 
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osteopontin, integrin α6 and β-catenin suggests that PTPL1 acts as a tumor suppressor 
whose downregulation or absence might relate to prostate cancer progression. 
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Figure legends 
Fig. 1 
PTPL1 downregulation induces changes in cell cycle. PC3 cells were silenced with a 
non-targeting control siRNA or with PTPL1 siRNA during 72 h and 96 h. (A) 
Downregulation of PTPL1 expression was monitored by RT-PCR. The quantity of 
PTPL1 transcript was divided by the quantity of HPRT1 to obtain a normalized value. 
(B) Cell cycle analysis by flow cytometry. Percentage of cells in different phases of the 
cell cycle was computed with ModFit software. (C) Proliferation assay. Cells silenced 
with control or PTPL1 siRNA were counted after 72 h and 96 h of silencing. (D) Flow 
cytometric analysis of BrdU incorporation after 72 h of silencing. (E) Western blot 
analysis of PTPL1, cyclin E, PCNA, cyclin B1, PTTG1 and phospho-histone H3 
proteins is shown. β-actin expression level was assessed to ensure equal protein loading. 
Densitometric analysis of protein expression levels are shown as histograms. Data 
represent the mean ± S.E.M. * P < 0.05 and ** P < 0.01 from Student’s t test. The 
experiments were performed at least three times. 
 
Fig. 2 
PTPL1 silencing increases the invasion ability of PC3 cells in vitro.  
(A) Wound healing assay was performed to determine siRNA control and siRNA 
PTPL1 PC3 cells motility. Quantification was carried out by measuring the wound area 
at 0 h and 36 h and calculating the percentage of wound closure for each condition. The 
experiment was performed three times. (B) Invasion assay with PC3 cells silenced with 
a non-targeting control siRNA or with PTPL1 siRNA during 24 h. Cells were then 
trypsinized, suspended in serum-free media and added to PET inserts uncoated (–ECM) 
or coated with Matrigel (+ECM). Cells were allowed to invade during 48 h and inserts 
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were processed as described in Materials and methods. The experiment was performed 
five times with each sample in duplicate. Data represent the mean ± S.E.M. * P < 0.05 
from Student’s t test, comparing siRNA control versus PTPL1 silenced cells. 
Representative photographs are shown.  
 
Fig. 3 
Quantitative real-time PCR analysis of PTPL1 and invasion-related genes in PC3 and 
DU145 cells silenced with a non-targeting control siRNA or with PTPL1 siRNA during 
72 h. (A) Downregulation of PTPL1 expression in PC3 and DU145 cells. The quantity 
of PTPL1 transcript was divided by the quantity of HPRT1 to obtain a normalized 
value. Data represent the mean of three experiments ± S.E.M. (B) Analysis of uPA, 
uPAR, tPA, PAI-1, integrin α6 (ITGA6) and osteopontin (OPN) expression in control 
and PTPL1-silenced PC3 and DU145 cells. The quantity of each transcript was divided 
by the quantity of HPRT1 to obtain a normalized value. Data represent the mean of 
three experiments ± S.E.M. * P < 0.05 and ** P < 0.01 from Student’s t test, comparing 
siRNA control versus PTPL1 silenced cells. 
 
Fig. 4 
Western blot analysis of PTPL1, active β-catenin, uPA, integrin α6 and osteopontin 
proteins in PC3 (A) and DU145 cells (B) silenced with a non-targeting control siRNA 
or with PTPL1 siRNA during 72 h and 96 h. β-actin expression level was assessed to 
ensure equal protein loading. Densitometric analysis of protein expression levels are 
shown as histograms. Bars represent the mean ± S.E.M. * P < 0.05 and ** P < 0.01 
from Student’s t test. The experiments were performed at least three times. 
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